Preventing ICU delirium
dc.contributor.author | Fourie C.E. | |
dc.date.accessioned | 2011-05-15T16:18:09Z | |
dc.date.available | 2011-05-15T16:18:09Z | |
dc.date.issued | 2003 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Article | |
dc.identifier.citation | Southern African Journal of Critical Care | |
dc.identifier.citation | 19 | |
dc.identifier.citation | 2 | |
dc.identifier.issn | 15628264 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/14536 | |
dc.subject | alcohol | |
dc.subject | analgesic agent | |
dc.subject | antiasthmatic agent | |
dc.subject | anticonvulsive agent | |
dc.subject | antihistaminic agent | |
dc.subject | antihypertensive agent | |
dc.subject | antiinfective agent | |
dc.subject | benzodiazepine derivative | |
dc.subject | beta adrenergic receptor blocking agent | |
dc.subject | cannabis | |
dc.subject | carbamazepine | |
dc.subject | catecholamine | |
dc.subject | cholinesterase inhibitor | |
dc.subject | clonidine | |
dc.subject | cocaine | |
dc.subject | corticosteroid | |
dc.subject | dexmedetomidine | |
dc.subject | digoxin | |
dc.subject | haloperidol | |
dc.subject | histamine H2 receptor antagonist | |
dc.subject | hypnotic agent | |
dc.subject | neuroleptic agent | |
dc.subject | opiate derivative | |
dc.subject | phencyclidine | |
dc.subject | phenytoin | |
dc.subject | propofol | |
dc.subject | psychedelic agent | |
dc.subject | sedative agent | |
dc.subject | unindexed drug | |
dc.subject | valproate semisodium | |
dc.subject | agitation | |
dc.subject | alcohol withdrawal | |
dc.subject | anticholinergic effect | |
dc.subject | article | |
dc.subject | attention | |
dc.subject | clinical feature | |
dc.subject | cognitive defect | |
dc.subject | competence | |
dc.subject | confusion | |
dc.subject | critical illness | |
dc.subject | delirium | |
dc.subject | delirium tremens | |
dc.subject | dystonia | |
dc.subject | environmental factor | |
dc.subject | extrapyramidal symptom | |
dc.subject | human | |
dc.subject | hypotension | |
dc.subject | intensive care unit | |
dc.subject | mental disease | |
dc.subject | morbidity | |
dc.subject | mortality | |
dc.subject | motor activity | |
dc.subject | neuroleptic malignant syndrome | |
dc.subject | neurologic examination | |
dc.subject | orientation | |
dc.subject | primary prevention | |
dc.subject | psychomotor disorder | |
dc.subject | QT prolongation | |
dc.subject | rating scale | |
dc.subject | risk assessment | |
dc.subject | risk factor | |
dc.subject | sedation | |
dc.subject | seizure | |
dc.subject | sleep waking cycle | |
dc.subject | treatment planning | |
dc.subject | urine retention | |
dc.subject | withdrawal syndrome | |
dc.subject | xerostomia | |
dc.title | Preventing ICU delirium | |
dc.type | Article |